Skip to content
Not for Human Consumption  |  Research Use Only
35% off your first purchase Use Code 35OFF
Society Peptides

CJC-1295, Ipamorelin and Tesamorelin: Two Receptors, Not One

In short
CJC-1295, Ipamorelin and Tesamorelin all get described as “growth hormone peptides”, which hides the thing that actually distinguishes them. They engage two entirely different receptors. Understanding which one a compound hits — and why the blends pair one of each — is the whole basis of this category.

Two receptors, not one

Growth hormone release from pituitary somatotrophs is governed by two separate input systems, and every compound in this category works through one or the other.

Pathway Receptor Native ligand Research compounds acting here
GHRH pathway GHRH receptor (GHRHR) Growth hormone-releasing hormone Tesamorelin, CJC-1295
Ghrelin pathway Growth hormone secretagogue receptor (GHSR) Ghrelin Ipamorelin

The two pathways are not redundant. GHRH signalling drives the amplitude of a release pulse; ghrelin-receptor signalling both stimulates release and suppresses somatostatin, the inhibitory brake on the system. Engaging one leaves the other untouched.

Why blends exist
A GHRH analog paired with a ghrelin-receptor secretagogue engages both inputs at once rather than pushing harder on one. That complementarity — not additive potency — is the stated rationale behind the combination products in this category.

The compounds individually

Tesamorelin

A GHRH analog, and the compound in this group with the most clinical development history behind it. It acts at the GHRH receptor and is the most straightforward member of the category: a modified version of the natural releasing hormone with improved stability.

CJC-1295

Also a GHRH analog, but engineered for duration. The distinction that causes the most confusion here is between the version with DAC (drug affinity complex) and the version without. The DAC modification allows binding to serum albumin, which extends the half-life dramatically; the version without DAC — sometimes called modified GRF(1-29) — is much shorter-acting. Material sold simply as “CJC-1295” may be either, so the distinction matters when reading protocols.

Ipamorelin

A growth hormone secretagogue acting at the ghrelin receptor, and notable in the literature for selectivity. Earlier secretagogues in its class showed appreciable effects on cortisol and prolactin; Ipamorelin was characterised as comparatively selective for GH release, which is the main reason it became the default ghrelin-pathway partner in blends.

Side by side

Tesamorelin CJC-1295 Ipamorelin
Receptor GHRH receptor GHRH receptor Ghrelin receptor (GHSR)
Class GHRH analog GHRH analog, duration-modified Growth hormone secretagogue
Key distinguishing feature Most clinical development history DAC vs non-DAC changes half-life substantially Characterised as selective for GH over cortisol and prolactin
Role in a blend GHRH-side partner GHRH-side partner Ghrelin-side partner
Pairs naturally with A ghrelin-pathway secretagogue A ghrelin-pathway secretagogue A GHRH analog

Reading the downstream axis

All of these compounds act upstream, on release. What happens next runs through the liver and the IGF-1 axis, which is why studies of secretagogues frequently report IGF-1 as a readout rather than growth hormone itself. GH is released in pulses and is awkward to sample meaningfully; IGF-1 is comparatively stable in circulation and integrates the signal over time.

If you are designing around this category, the IGF-1 research guide covers the downstream half of the axis, including the binding-protein layer that determines how much IGF-1 is actually available to act.

Growth hormone axis research materials
IGF-1 1mg$124.99
All materials supplied for laboratory research use only.

Handling notes

These are conventional lyophilized peptides and follow standard practice — equilibrate the sealed vial before opening, reconstitute gently in bacteriostatic water, aliquot before freezing, and keep dry stock frozen. Blend vials contain two peptides in fixed proportion, so the reconstitution volume sets both concentrations at once; record the ratio alongside the concentration when you label the vial.

Frequently asked questions

What is the difference between a GHRH analog and a secretagogue?
They act on different receptors. GHRH analogs such as Tesamorelin and CJC-1295 engage the GHRH receptor. Secretagogues such as Ipamorelin engage the ghrelin receptor. Both routes influence GH release, through separate input systems.
Why are CJC-1295 and Ipamorelin sold together?
Because they engage the two different pathways rather than the same one. The stated rationale for blends is complementarity across both inputs, not simply a larger dose of one.
What does DAC mean in CJC-1295?
Drug affinity complex — a modification allowing the peptide to bind serum albumin, substantially extending its half-life. CJC-1295 without DAC is much shorter-acting, so it is worth confirming which version a protocol refers to.
Why is Ipamorelin described as selective?
Earlier compounds in its class showed appreciable effects on cortisol and prolactin alongside GH. Ipamorelin was characterised as comparatively selective for GH release, which is why it became the standard ghrelin-pathway partner.
How does Tesamorelin differ from CJC-1295?
Both are GHRH analogs acting at the same receptor. Tesamorelin has the more substantial clinical development history; CJC-1295 is distinguished mainly by the duration engineering of its DAC form.
Why do studies measure IGF-1 instead of growth hormone?
GH is released in pulses, making single measurements hard to interpret. IGF-1 is more stable in circulation and integrates the signal, so it is commonly used as a downstream readout.

References

1. Growth hormone secretagogue receptor and ghrelin signalling — literature overview. PubMed
2. GHRH analogs and pituitary somatotroph signalling. PubMed
3. Ipamorelin selectivity characterisation. PubMed
4. Bachem. Handling and Storage Guidelines for Peptides. bachem.com
Research use only. The materials discussed here are supplied by Peptide Society exclusively for laboratory research and analytical applications. They are not approved by the FDA for human or veterinary use, are not medications, dietary supplements, cosmetics or food products, and must not be consumed or administered. Nothing here is medical advice.